Business Wire

CA-HILLSTONE-NETWORKS

7.6.2022 08:02:11 CEST | Business Wire | Press release

Share
Hillstone Networks Delivers Cyber Resilience to Customers through Robust Solution Portfolio

Hillstone Networks , a leading provider of innovative and accessible cybersecurity solutions, today announced the global availability of their simplified portfolio that delivers on cyber resilience, securing critical assets against sophisticated, multifaceted cyberattacks and an expanding attack surface.

Today’s workforce and workloads require flexibility, quality of service, and above all, protection. Security solutions need to be equally flexible and deliver on enterprise-grade cyber resilience. The Hillstone Networks solutions have evolved from a network security platform, included in the Gartner Magic Quadrant for Enterprise Firewalls for 8 consecutive years, into a robust portfolio that delivers on cyber resilience, from edge to cloud, and everything in between, to over 23,000 customers worldwide.

At RSAC 2022, in San Francisco, Hillstone will showcase its broad range of solutions across these initiatives:

  • SD-WAN : Hillstone Secure SD-WAN secures today’s borderless networks with granular visibility and enforcement into all interactions across all entry points into the network, with the ability to drill further into user, device, and access behavior.
  • ZTNA : Hillstone ZTNA solution secures remote access for today’s work-from-anywhere deployments, or heavily regulated industries with sensitive data that need to secure their evolving edge perimeter. Fine-grained access controls allow for precise enforcement of privileges from wherever it’s needed.
  • Microsegmentation : Hillstone CloudHive protects cloud-native and cloud-based apps, for dev/ops teams who rely on app portability and microservices, and cloud service providers where multi-tenancy can be risky without segmenting or isolating network access. Support for both VMware and OpenStack provide cross-platform portability across clouds.
  • CWPP : Hillstone CloudArmour protects cloud applications running in public or multiple cloud environments, integrating into existing CI/CD and DevOps environments and processes with full application stack visibility. Protect bare metal hosts, virtual machines, containers, and serverless workloads.
  • NDR : Hillstone sBDS delivers continuous network monitoring with an AI-driven network detection and response platform that collects and aggregates network traffic data, applying behavioral analysis and AI/ML, and delivering insights to security teams from a single view.
  • XDR : Hillstone iSource rolls up all the key activities including threat detection, investigation, response, and real-time threat hunting into a single platform and get extensive visibility across all relevant threat data from device endpoints, applications, networks, and security devices, including 3rd party devices.

“Cyber-resiliency is the infrastructure’s ability to weather a storm of relentless attacks and bounce quickly back. Cyber-resilient infrastructure transforms traditional security, which is inflexible, static, and impractical, into a modernized and agile security plan that’s adaptive, dynamic, and realistic. This is the Hillstone vision and reflected in the solutions we deliver to the market,” states Tim Liu, CTO and co-founder, Hillstone Networks.

"Today's typical IT infrastructure environment is highly disaggregated in nature and presents complex challenges with respect to security. I believe Hillstone Networks delivers a suite of AI/ML enhanced cybersecurity solutions that are designed to provide visibility, ease of deployment, and simplify ongoing management through integration into existing SecOps frameworks," states Will Townsend, Vice President & Principal Analyst, Networking & Security Practices, Moor Insights & Strategy.

About Hillstone Networks

Hillstone Networks' innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyberthreats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/Hillstone-Networks-230976560386832/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye